Back to News
Apr 8, 2026 8:10 AM

Life Biosciences Secures $80 Million Series D Financing

BOSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Life Biosciences, Inc., ("Life Bio") a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the close of a fully-subscribed $80 million financing. The proceeds will support the company's operations into the second half of 2027, including the completion of its recently initiated Phase 1 clinical trial of ER-100 and the continued advancement of its broader Partial Epigenetic Reprogramming (PER) platform across multiple therapeutic indications.

"We are encouraged by the strong participation in this financing, which reflects the growing interest in our platform and the opportunity we have to reverse multiple diseases of aging," said Jerry McLaughlin, Chief Executive Officer, Life Biosciences. "This support enables us to advance our lead program, ER-100, through key clinical milestones while continuing the expansion of our pipeline, positioning Life Bio to deliver disease-modifying solutions for patients."

Aging is the biggest risk factor for most chronic diseases, with ...